Prelude Therapeutics (PRLD, Financial) has received a reaffirmation of confidence from HC Wainwright & Co. The analyst, Robert Burns, has reiterated a "Buy" rating for the stock, according to the latest report released on May 5, 2025.
The investment bank has maintained its price target for PRLD at $5.00 USD, unchanged from the previous target. This decision underscores the analyst's consistent outlook on the company's future performance.
The stock rating and price target have been stable, with HC Wainwright showing continued optimism for Prelude Therapeutics (PRLD, Financial) as it progresses in its endeavors. Investors and stakeholders should note the ongoing support demonstrated by this reiterated rating and maintained price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Prelude Therapeutics Inc (PRLD, Financial) is $5.00 with a high estimate of $10.00 and a low estimate of $1.00. The average target implies an upside of 463.44% from the current price of $0.89. More detailed estimate data can be found on the Prelude Therapeutics Inc (PRLD) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Prelude Therapeutics Inc's (PRLD, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
